Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin
This article was originally published in Pharmaceutical Approvals Monthly
The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use
You may also be interested in...
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
Deal is "strikingly similar" to a collaboration forged with Novartis for an anti-thrombotic earlier this year.
Approval could be pushed out to 2010 if the agency wants to review data from the ATLAS study, which completed too late to get into the NDA package.